Northwest Biotherapeutics (NWBO)
(Delayed Data from OTC)
$0.48 USD
0.00 (0.63%)
Updated Apr 26, 2024 02:25 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Northwest Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 2 | 1 | 1 | 2 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 2 | 2 | 1 | 1 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 57 | 69 | 54 | 88 | 30 |
Income After Depreciation & Amortization | -56 | -67 | -53 | -87 | -27 |
Non-Operating Income | -2 | -32 | 237 | -435 | 10 |
Interest Expense | 5 | 6 | 5 | 9 | 3 |
Pretax Income | -63 | -105 | 179 | -530 | -20 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -63 | -105 | 179 | -530 | -20 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -63 | -105 | 179 | -530 | -20 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -52 | -63 | -50 | -84 | -26 |
Depreciation & Amortization (Cash Flow) | 4 | 4 | 3 | 3 | 1 |
Income After Depreciation & Amortization | -56 | -67 | -53 | -87 | -27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1,119.19 | 1,015.85 | NA | NA | 564.19 |
Diluted EPS Before Non-Recurring Items | -0.06 | -0.10 | NA | NA | -0.04 |
Diluted Net EPS (GAAP) | -0.06 | -0.10 | -0.06 | -0.73 | -0.04 |
Fiscal Year end for Northwest Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.45 | 0.41 | 0.20 | 0.88 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.45 | 0.41 | 0.20 | 0.88 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 15.58 | 14.23 | 13.77 | 13.84 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -15.13 | -13.82 | -13.57 | -12.96 |
Non-Operating Income | NA | -2.54 | -3.09 | 0.43 | 3.34 |
Interest Expense | NA | 1.24 | 1.67 | 1.30 | 1.03 |
Pretax Income | NA | -18.92 | -18.58 | -14.45 | -10.65 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -18.92 | -18.58 | -14.45 | -10.65 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -18.92 | -18.58 | -14.45 | -10.65 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 1,119.19 | 1,134.36 | 1,108.42 | 1,074.90 |
Diluted EPS Before Non-Recurring Items | NA | -0.02 | -0.02 | -0.01 | -0.01 |
Diluted Net EPS (GAAP) | NA | -0.02 | -0.02 | -0.01 | -0.01 |